Pending Contracts. Legal Representative Agreement by and between Alxx Xxxx Xonsultants Ltd. and the Assignor. Clinical Trial Agreement by and between Sydney Local Health District (SLHD) and the Assignor. (Project: AAV8-hFIX19-101 Study) Clinical Trial Agreement by and between St. James’s Hospital (Dublin, Ireland) and the Assignor. (Project: AAV8-hFIX19-101 Study) Clinical Trial Agreement by and between The State University of Campinas (Brazil) and the Assignor. (Project: AAV8-hFIX19-101 Study) Clinical Trial Agreement by and between University of California, San Francisco and the Assignor. (Project: AAV8-hFIX19-101 Study) Master Service Agreement by and between Quintiles, Inc. and the Assignor. (Project: AAV8-hFIX19-101 Study International Site Monitoring) Business Associate Agreement by and between Quintiles, Inc. and the Assignor. (Project: AAV8-hFIX19-101 Study International Site Monitoring) Contract Service Agreement by and between Caxxxxx Xaboratories, Inc. and the Assignor. (Project: AAV2-hCHM-101 Study) LICENSE AGREEMENT AMENDMENT This Amendment (hereinafter “Amendment”), with an effective date of December 26th, 2013 (the “Effective Date”) serves as a modification to the License Agreement, having an effective date of October 14, 2013 (the “Agreement”), made by and between Spark Therapeutics, LLC, (formerly known as AA Venue Therapeutics, LLC) a limited liability company organized and existing under the laws of Delaware and having a principal place of business at 34xx xxx Xxxxx Xxxxxx Xxxx, Xxxxxxxxxxxx, XX 00000 (“Company”) and The Children’s Hospital of Philadelphia, a non-profit entity organized and existing under the laws of Pennsylvania and having a principal place of business at 34th and Cixxx Xxxxxx Xxxxxxxxx, Xxxxxxxxxxxx, XX 00000 (“CHOP”).
Appears in 4 contracts
Samples: License Agreement (Spark Therapeutics, Inc.), License Agreement (Spark Therapeutics, Inc.), License Agreement (Spark Therapeutics, Inc.)